PF-Atlas › Treatments › Senolytics + WNT Agonist Combination
Senolytics + WNT Agonist Combination
Sequential: D+Q clears senescent cells, RSPO3 expands AEC2 pool
Clinical research — In human clinical trials (Phase I–III). How PF-Atlas grades evidence.
Development stage
Concept/Preclinical
Evidence level
Rational Combination
Mechanism class
Sequential: D+Q clears senescent cells, RSPO3 expands AEC2 pool
Timeline
2-4 years
Risk profile
Low-Medium
Developer
UCSF / Mayo
Key researchers
H. Chapman / J. Kirkland
Overview
Novel sequential protocol. Highest regenerative potential of any near-term strategy.
How Senolytics + WNT Agonist Combination fits into IPF treatment
Senolytics + WNT Agonist Combination is classified as Rational Combination at the Concept/Preclinical stage. Explore how it compares to other options and where it sits in the development pipeline:
Other IPF treatments
Medical disclaimer. This page summarizes published research and PF-Atlas model output about Senolytics + WNT Agonist Combination for information only. It is not medical advice or a treatment recommendation. Drug availability, approval status and evidence change — verify with a pulmonologist and official sources (FDA, ClinicalTrials.gov) before any decision.